Device Trial Radar · NCT03103282
Post-market Clinical Study to Confirm Safety and Performance of PuraStat® for the Management of Bleeding in Vascular Surgery.
Last checked: Nov 20, 2026Latest source record: Dec 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
65
Actual
Start
Jun 14, 2017
Primary completion
Jul 5, 2019
Study completion Aug 30, 2019
Sponsor
- Lead sponsor
- 3-D Matrix Europe SASNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 6, 2017
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The objective of this post-market clinical follow-up study is to collect medical information on patients implanted with PuraStat®, according to each participating institution's procedures and standards of care.
Conditions
- Vascular Anastomosis Surgery
Interventions
PuraStat®Device
Synthetic haemostatic material
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Time-To-HaemostasisTime frame: Intraoperatively
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St George'S University Hospitals Nhs Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.